Disappointingly, the first clinical trials that were conducted with small molecule EGFR inhibitors, including gefitinib and erlotinib that had shown success for other tumor types, did not show any encouraging results for glioma treatment [189–191]. Here, EGFR is linked to central nervous system cancer.